Single and Multiple Ascending Dose Study of AMG 378 in Healthy Participants
A Phase 1 Randomized, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose and Food-effect Study to Evaluate the Safety, Tolerability, Pharmacokinetics of AMG 378 in Healthy Participants
Sponsor: Amgen
Terminated
Business Decision
Listed as NCT06910709, this PHASE1 trial focuses on Healthy Volunteers and remains terminated or withdrawn. Sponsored by Amgen, it has been updated 4 times since 2025, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
4 versions recorded-
Feb 2026 — Present [monthly]
Terminated PHASE1
Status: Recruiting → Terminated
-
Dec 2025 — Feb 2026 [monthly]
Recruiting PHASE1
-
Jul 2025 — Dec 2025 [monthly]
Recruiting PHASE1
-
May 2025 — Jul 2025 [monthly]
Recruiting PHASE1
First recorded
Apr 2025
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Amgen
For direct contact, visit the study record on ClinicalTrials.gov .